GLAS
Global Loan Agency Services Limited (part of the global GLAS Group) is thrilled to announce the successful completion of its acquisition of Pristine. This marks the first acquisition by the GLAS Group, and also represents a key milestone in the organisation’s ambitious roadmap to deepen its presence in Europe.
This transaction was agreed in August 2023 subject to regulatory approval and customary closing conditions, with completion occurring in March 2024.
Pristine
Pristine is a leading fiducie and asset management business. It was established in Paris in 2016 and is regulated by the Autorité des Marchés Financiers (AMF).
Pristine provides a complementary set of services which include fiducie, fund structuring and administration services to both international and domestic institutions with the primary purpose of facilitating corporate financing activity for non-bank and bank lenders in France.
The firm has a deep and diversified history in restructuring, securitisation, structured finance, and other ad hoc financing projects.
GLAS France
The GLAS Group launched its French operations in Paris in 2018 and has since built out a sizeable team led by Aymeric Mahe, Head of GLAS SAS.
GLAS SAS is the only non-bank, independent company regulated by the Autorité de Contrôle Preduentiel et de Résolution (ACPR) to administer payments in France on loan transactions that forms part of a global group.
In addition to loan agency services, GLAS provides a range of institutional debt administration to domestic and international debt funds, corporates, and bulge bracket banks globally.
The firm is a market-leading provider in direct and syndicated lending, high yield, leveraged finance and capital market debt issuance.
GLAS SAS has also been involved with numerous high-profile restructuring cases in France such as SMCP, Orpea, Technicolor and Pierre & Vacances.
GLAS founders Mia Drennan and Brian Carne said:
“We are excited to finalise the Group’s first ever acquisition and further expand GLAS’s service capabilities. The AMF and ACPR regulatory permissions of Pristine and GLAS, along with our collective expertise and reputations in the debt markets, will allow us to offer an expanded offering of relevant services to our enlarged client base.”
Pristine Président, Renaud Baboin said:
“This acquisition signals the start of a fantastic partnership between GLAS and Pristine. The two companies are well matched across all aspects of the respective businesses and culture, and I am excited to see how the respective businesses flourish as a result."
Pristine Directeur Général, Benjamin Raillard added:
“We are happy to announce the closure of this transaction and begin integrating Pristine with the GLAS Group. It is an exciting time for the group and our customers who will soon be able to benefit from the synergies of the two organisation’s expertise. We are confident that this partnership will be a fruitful one for all involved.”
GLAS and Pristine’s plan for the future
The conclusion of this acquisition signifies GLAS’s commitment to offering an expanded suite of products and services to meet the needs of clients who participate in originating debt or investing in financial transactions in Europe.
The Pristine team will be located at GLAS SAS’s new Paris office on Avenue George V.
The two organisations will be continue to be separately regulated by the AMF and the ACPR. The two licences will allow GLAS and Pristine to offer an enhanced service to more customers on a greater number of transactions.
Since the original announcement of the proposal to acquire Pristine, GLAS have also, subject to regulatory approval, committed to partnering with Singaporean-based Watiga. Watiga will also join the GLAS Group’s global network.
About GLAS
GLAS was established in 2011 by Mia Drennan and Brian Carne. Today, it is the premier independent, non-creditor, conflict-free provider of loan administration and bond trustee services known for its white glove service and expertise on complex deal execution.
GLAS is a global company and is located in the USA, Europe, and APAC, with headquarters in London. GLAS services in excess of €360bn of assets under administration on a daily basis and employs over 300 professionals in the Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401726218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom